

# Sara Llufriu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9227802/publications.pdf>

Version: 2024-02-01

89  
papers

3,933  
citations

147566

31  
h-index

133063

59  
g-index

96  
all docs

96  
docs citations

96  
times ranked

6081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. <i>Neuroradiology</i> , 2022, 64, 1383-1390.	1.1	2
2	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. <i>Frontiers in Immunology</i> , 2022, 13, 842354.	2.2	1
3	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 743.	1.1	6
4	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. <i>Network Neuroscience</i> , 2022, 6, 916-933.	1.4	10
5	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	2.8	20
6	A NOTCH3 homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke. <i>Journal of Neurology</i> , 2021, 268, 810-816.	1.8	11
7	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
8	Taking care of kidney transplant recipients during the COVID-19 pandemic: Experience from a medicalized hotel. <i>Clinical Transplantation</i> , 2021, 35, e14132.	0.8	5
9	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1706-1716.	1.4	8
10	Incidence and Impact of COVID-19 in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	29
11	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. <i>NeuroImage: Clinical</i> , 2021, 30, 102653.	1.4	21
12	Accelerated white matter lesion analysis based on simultaneous $T_1$ and $T_2$ quantification using magnetic resonance fingerprinting and deep learning. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 471-486.	1.9	12
13	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
14	Lesion probability mapping in MS patients using a regression network on MR fingerprinting. <i>BMC Medical Imaging</i> , 2021, 21, 107.	1.4	3
15	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 16805.	1.6	17
16	Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers. <i>Scientific Data</i> , 2021, 8, 219.	2.4	27
17	Generic acquisition protocol for quantitative MRI of the spinal cord. <i>Nature Protocols</i> , 2021, 16, 4611-4632.	5.5	65
18	Fully automated delineation of the optic radiation for surgical planning using clinically feasible sequences. <i>Human Brain Mapping</i> , 2021, 42, 5911-5926.	1.9	5

#	ARTICLE	IF	CITATIONS
19	CSF Chitinase 3- $\beta$ -Glucosaminidase 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
20	Diffusion-Weighted Imaging: Recent Advances and Applications. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 490-506.	0.7	30
21	A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa592.	0.4	7
22	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1107.	1.1	8
23	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 234.	4.5	17
24	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101483.	0.9	23
25	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. <i>NeuroImage: Clinical</i> , 2020, 28, 102411.	1.4	11
26	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 581700.	1.1	8
27	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. <i>Scientific Reports</i> , 2020, 10, 13333.	1.6	20
28	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. <i>NeuroImage</i> , 2020, 218, 116956.	2.1	135
29	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020, 41, 1308-1320.	1.1	1
30	Abstract 15640: Long Term Moderate, but Not Intense, Exercise Improves Cognitive Brain Health. Study in a Rat Model. <i>Circulation</i> , 2020, 142, .	1.6	0
31	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
32	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8463-8470.	3.3	112
33	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	44
34	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. <i>Scientific Reports</i> , 2019, 9, 20172.	1.6	10
35	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	1.8	47
36	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 333-339.	0.9	17

#	ARTICLE	IF	CITATIONS
37	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 230-234.	0.9	18
38	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 801-810.	1.4	17
39	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
40	Time efficient whole-brain coverage with MR Fingerprinting using slice-interleaved echo-planar-imaging. <i>Scientific Reports</i> , 2018, 8, 6667.	1.6	29
41	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.4	122
42	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1246.	4.5	32
43	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	4.9	422
44	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878000.	1.5	7
45	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2018, 20, 161-168.	1.4	22
46	Predictors of vision impairment in Multiple Sclerosis. <i>PLoS ONE</i> , 2018, 13, e0195856.	1.1	21
47	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	1.4	77
48	Vanishing spinal cord after varicella-zoster virus myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e364.	3.1	1
49	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1762-1771.	1.4	8
50	Structural networks involved in attention and executive functions in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 13, 288-296.	1.4	87
51	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 367-372.	1.5	9
52	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
53	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 436-440.	1.5	43
54	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36

#	ARTICLE	IF	CITATIONS
55	Visual field impairment captures disease burden in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 695-702.	1.8	14
56	Enhanced mirror activity in $\sim$ crossed $\hat{e}$ ™ reaction time tasks in multiple sclerosis. <i>Clinical Neurophysiology</i> , 2016, 127, 2001-2009.	0.7	5
57	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 564-568.	1.4	36
58	Improved Framework for Tractography Reconstruction of the Optic Radiation. <i>PLoS ONE</i> , 2015, 10, e0137064.	1.1	39
59	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
60	Lipid-specific immunoglobulin $\langle$ scp $\rangle$ M $\langle$ /scp $\rangle$ bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	2.8	48
61	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. <i>Journal of Neurology</i> , 2015, 262, 219-221.	1.8	3
62	Dynamics of retinal injury after acute optic neuritis. <i>Annals of Neurology</i> , 2015, 77, 517-528.	2.8	142
63	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. <i>Journal of the Neurological Sciences</i> , 2015, 352, 127-128.	0.3	6
64	Walking function in clinical monitoring of multiple sclerosis by telemedicine. <i>Journal of Neurology</i> , 2015, 262, 1706-1713.	1.8	22
65	Autoimmune post-herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.5	226
66	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. <i>Journal of Neurology</i> , 2015, 262, 2491-2497.	1.8	35
67	Defective sensorimotor integration in preparation for reaction time tasks in patients with multiple sclerosis. <i>Journal of Neurophysiology</i> , 2015, 113, 1462-1469.	0.9	17
68	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. <i>Journal of the Neurological Sciences</i> , 2015, 359, 146-150.	0.3	8
69	Abnormal Control of Orbicularis Oculi Reflex Excitability in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e103897.	1.1	14
70	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e113936.	1.1	131
71	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. <i>BMC Research Notes</i> , 2014, 7, 910.	0.6	26
72	Cognitive functions in multiple sclerosis: impact of gray matter integrity. <i>Multiple Sclerosis Journal</i> , 2014, 20, 424-432.	1.4	47

#	ARTICLE	IF	CITATIONS
73	Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis. <i>Lupus</i> , 2014, 23, 1555-1556.	0.8	1
74	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 840.	4.5	57
75	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. <i>Annals of Neurology</i> , 2014, 75, 98-107.	2.8	206
76	Colour vision impairment is associated with disease severity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1207-1216.	1.4	35
77	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 742-748.	1.4	35
78	Retrograde retinal damage after acute optic tract lesion in MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 824-826.	0.9	22
79	Changes in Your Breathing Can Change Your Brain. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 763-764.	2.5	2
80	White and Gray Matter Impairment in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 207-208.	2.5	0
81	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 244, 103-106.	1.1	21
82	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. <i>PLoS ONE</i> , 2012, 7, e37167.	1.1	68
83	Rapidly progressive diffuse Lewy body disease. <i>Movement Disorders</i> , 2011, 26, 1316-1323.	2.2	56
84	Reply: Rapidly progressing diffuse Lewy body disease. <i>Movement Disorders</i> , 2011, 26, 2585-2585.	2.2	0
85	T2 hypointense rims and ring-enhancing lesions in MS. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1317-1325.	1.4	16
86	Plasma exchange for acute attacks of CNS demyelination. <i>Neurology</i> , 2009, 73, 949-953.	1.5	174
87	Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study. <i>Journal of Neuroimmunology</i> , 2009, 215, 31-35.	1.1	91
88	Familial Sneddon's syndrome with microbleeds in MRI. <i>BMJ Case Reports</i> , 2009, 2009, bcr2007131912-bcr2007131912.	0.2	2
89	Familial Sneddon's syndrome with microbleeds in MRI. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 962-962.	0.9	9